- Home
- PTGX
as 06-17-2025 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.9B | IPO Year: | 2016 |
| Target Price: | $67.11 | AVG Volume (30 days): | 860.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.86 | EPS Growth: | -68.10 |
| 52 Week Low/High: | $30.67 - $60.60 | Next Earning Date: | 08-05-2025 |
| Revenue: | $207,801,000 | Revenue Growth: | -34.02% |
| Revenue Growth (this year): | -81.42% | Revenue Growth (next year): | 52.36% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
MT Newswires
20 hours ago
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target
Argus Research
7 days ago
PTGX: Rating decreased to a HOLD
The Wall Street Journal
9 days ago
For Patients With Rare Blood Cancer, New Drug Offers Relief
Simply Wall St.
13 days ago
Exploring Three High Growth Tech Stocks In The US Market
MT Newswires
16 days ago
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint
Business Wire
17 days ago
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Insider Monkey
22 days ago
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
ACCESS Newswire
a month ago
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.